Please assess the completion status of the following clinical trial:

Trial Title: Deposition of Inhaled Prolastin in Cystic Fibrosis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with diagnosis of CF~* Age \>= 8 years~* Forced expiratory volume at one second (FEV1) \> 25 % of predicted value~* Free elastase activity checked at visit 1 must be positive (free elastolytic activity in the sample, 2 standard deviations above of the negative blank samples in the assay.) .~* Patient must be positive at least 3 times for pseudomonas in the last 2 years~* Patient must be positive for pseudomonas at Visit 1~* Patient must be able to perform reliable spirometry~* Patient must be on stable concomitant therapy at least 2 weeks prior to visit 1 and during the study~* Written informed consent of the patient or legal representative(s)~Exclusion Criteria:~* FEV1 \< 25% of predicted value post-bronchodilator~* History of lung transplant~* Any lung surgery within the past 2 years~* On any thoracic surgery waiting list~* Severe concomitant disease (serious malignant disease, congestive heart failure New York Heart Association (NYHA) III/IV, cor pulmonale with the need of oxygen therapy)~* Severe liver cirrhosis with ascites, hypersplenism or grade III/IV esophageal varices.~* Known selective immunoglobulin A (IgA) deficiency with known antibody against IgA (anti-IgA antibody)~* Active pulmonary exacerbation within the 4 weeks prior to screening~* Current Smoking~* Pregnancy or lactation~* Women of child-bearing age without adequate contraception~* Any medical condition which the investigator feels will prohibit the patient from completing the trial~* Participation in another clinical trial within 30 days prior to inclusion at visit 1

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Bronchial Deposition Intervention: Alpha1-Proteinase Inhibitor (Human) Dosage: 25 mg in lungs, one inhalation per day over 4 weeks
- Group 2 (Type: EXPERIMENTAL): Peripheral Deposition Intervention: Alpha1-Proteinase Inhibitor (Human) Dosage: 25 mg in lungs, one inhalation per day over 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).